ACADHealthcareMid-Cap
ACADIA PHARMACEUTICALS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for ACADIA PHARMACEUTICALS INC (ACAD), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ACAD insiders buying or selling?
ACADIA PHARMACEUTICALS INC insiders reported 5 open-market buys ($341.5M) and 153 sells ($73.7M) across 158 Form 4 filings — a net buying position of $267.8M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 29, 2026)
Total Form 4 filings
158
SEC EDGAR
Insider filers
16
Insider buys (5)
$341.5M
Insider sells (153)
$73.7M
Insider sentiment
Net buyingNet insider flow of $267.8M in net buying.
Recent ACAD insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 11.4K | $26.08 | $297.9K |
| May 27, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 5.4K | $21.18 | $114.4K |
| May 5, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.3K | $21.79 | $29.0K |
| May 5, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $21.79 | $76.4K |
| Apr 7, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.7K | $22.20 | $60.1K |
| Apr 7, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.0K | $22.20 | $22.9K |
| Mar 27, 2026 | Adams Catherine Owen | Chief Executive Officer | Sale | 11.6K | $21.47 | $249.9K |
| Mar 27, 2026 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Sale | 3.8K | $21.47 | $82.5K |
| Mar 27, 2026 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | Sale | 3.4K | $21.47 | $73.7K |
| Mar 27, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.9K | $21.57 | $41.9K |
| Mar 27, 2026 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 7.4K | $21.55 | $159.1K |
| Feb 10, 2026 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Sale | 7.0K | $23.38 | $162.5K |
| Nov 19, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 10.3K | $23.69 | $243.1K |
| Nov 19, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 4.1K | $23.69 | $96.8K |
| Nov 12, 2025 | James M Daly | Director | Sale | 30.0K | $22.37 | $671.0K |
| Sep 16, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $23.65 | $82.7K |
| Sep 3, 2025 | Elizabeth A. Garofalo | Director | Sale | 1.6K | $25.98 | $41.6K |
| Aug 19, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 22.0K | $25.18 | $554.0K |
| Jun 5, 2025 | Laura Brege | Director | Sale | 14.4K | $21.78 | $314.6K |
| May 20, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 4.0K | $22.50 | $90.0K |
| May 20, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.0K | $25.00 | $50.0K |
| May 3, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.3K | $14.60 | $19.4K |
| May 2, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 3.5K | $14.60 | $51.1K |
| Apr 8, 2025 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.7K | $14.82 | $40.1K |
| Apr 8, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale | 1.0K | $14.82 | $15.2K |
Showing the 25 most recent of 158 Form 4 filings for ACADIA PHARMACEUTICALS INC.
Most active ACAD insiders
- Mark C. Schneyer26 filings
- James Kihara25 filings
- Stephen Davis25 filings
- Srdjan R. Stankovic18 filings
- Brendan Teehan16 filings
Ask anything about ACAD insider activity
Use Trabud's AI agent to query ACADIA PHARMACEUTICALS INC's Form 4 history in plain English — "Show me ACAD CEO purchases this year" or compare it against any other ticker.
Open the AI agentACAD insider trading FAQ
Are ACADIA PHARMACEUTICALS INC insiders buying or selling?
Across 158 SEC Form 4 filings, ACADIA PHARMACEUTICALS INC (ACAD) insiders reported 5 open-market purchases totaling $341.5M and 153 sales totaling $73.7M. That is a net buying position of $267.8M.
How many insiders trade ACAD stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ACADIA PHARMACEUTICALS INC. The most recent filing was accepted on Jun 29, 2026.
Where does Trabud get ACAD insider trading data?
All ACAD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.